Navigation Links
Memry Corporation FY 2007 Revenues $51.7M; Net Income $317,000 or $0.01 Per Share
Date:9/17/2007

Q4 Nitinol and Polymer Sales Up From Q3

BETHEL, Conn., Sept. 17 /PRNewswire-FirstCall/ -- Memry Corporation (Amex: MRY), a leading provider of nitinol and polymer components to the medical device industry, reported today revenues of $51,677,000 for the fiscal year ended June 30, 2007 versus $52,588,000 in fiscal year 2006. Net income for fiscal 2007 was $317,000, or $0.01 per diluted share, compared with net income of $2,673,000, or $0.09 per diluted share, for the previous fiscal year.

For the fourth fiscal quarter ended June 30, 2007, revenues were $13,129,000, compared with $13,279,000 in the fourth fiscal quarter of 2006. Fourth quarter net income was $42,000, or $0.00 per diluted share, compared with net income of $887,000, or $0.03 per diluted share, in the comparable period of fiscal year 2006.

Memry Chief Executive Officer Robert Belcher said, "Although this has been an extremely difficult year for Memry, our fourth quarter financial results were stronger than we expected and, as we announced in our preliminary report last month, we believe Memry has turned the corner. In the fourth fiscal quarter both nitinol and polymer sales resumed growth on a sequential quarter basis. Thanks to our strong cash flow, total debt was reduced from $10.0 million a year ago to $1.6 million at June 30, 2007.

"We are encouraged with both the revenue and net income results achieved in the fourth quarter. Although modest, the $42,000 net income in the fourth quarter is the first positive net income quarter since the first quarter of the 2007 fiscal year.

"Our fourth quarter revenue results showed Memry is rebounding from the weakness we experienced simultaneously in both our nitinol and p
'/>"/>

SOURCE Memry Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Shorter infants have lower incomes in later life
3. Research shows that death may occur differently depending on the income level
4. Education And Income Level May Not Guarantee Health
5. The trident of unhealthy teen choices is early Lunch, Soft Drink Machine Income and Parents who relent
6. Health Insurance for Low-Income Expats in UAE
7. Classes on Proper Use of Diet Supplements for Low Income Group Elders
8. Spouses Income Taken Into Account In Nursing Home Charges
9. The higher the income the lower the disability rates!
10. Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks
11. Social Drinking Increases Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...nversations with alleged lesbian pal deejay Samant... Girls' star kept in touch with her friends and re... magazine the access to the starlet's passionate c...n. In the conversations that appear under the tit...
...otect against the clustering of abnormal body chem... study in the Journal of Epidemiology and Communit...eased risk of diabetes, coronary artery disease, a...based on a representative sample of 2375 men aged ...
... Physicians (UK), the state of emergency services... audit entitled Myocardial Infarction National Aud...all in the percentage of people killed by heart at...wn 12.4 percent from last years figures, meaning 1...
...tion programs in low and middle-income countries, ...am unit costs to reduce . A UCSF-led team of rese... Other low and middle-income countries like Uganda... Russia were also assessed. "With the recent rep...
Other Medicine News:Health News:Survey Shows Emergency Services Of British Hospitals Doing A Good Job 2
(Date:8/18/2008)...sed life expectancy for people with,Down syndrome,...n the world of Down,syndrome, ,Mr. C, is a rarity.... the past 16 years, at seventy, ,Mr. C, has well s...ith Down syndrome, currently in the,late fifties, ...Mr. C, does,not exhibit clinical symptoms of Alzhe...
(Date:8/18/2008)...ntly in Phase I -, PRINCETON, N.J. and SAN DIEGO,... a clinical stage biotechnology company committed ...-threatening and life-altering,infectious diseases...,772,B2 by the U.S. Patent and Trademark Office, c...ently in Phase I development for the treatment of ...
(Date:8/14/2008)...Call/ -- AstraZeneca (NYSE: AZN ),today announced...ancer,Centre Singapore (NCCS) and the National Uni...ounds. The collaboration, which is spelt out in a,...today, aims to further,build AstraZeneca,s drug de...d up access to new medicines of potential benefit ...
(Date:8/14/2008)...wswire/ -- The Clinical Trials,Bootcamp announces ...s,clinical coordinators, clinical research staff ...be held in Boca Raton at the Boca Resort from May,...oordinators, monitors and,other industry personnel...,clinical trials into a practice, as well as how t...
Breaking Medicine Technology:Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 2Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Independence Blue Cross Gives Grants to Support Health Care for the Uninsured 7760 1Independence Blue Cross Gives Grants to Support Health Care for the Uninsured 7760 2David Luci Joins MacroChem as General Counsel and Vice President Corporate Development 7758 1David Luci Joins MacroChem as General Counsel and Vice President Corporate Development 7758 2David Luci Joins MacroChem as General Counsel and Vice President Corporate Development 7758 3David Luci Joins MacroChem as General Counsel and Vice President Corporate Development 7758 4Millennium Ships and Records the First 24200 000 of Revenue Generated From the Five Year 2420 000 000 Exclusive Purchase Order 2095 1Millennium Ships and Records the First 24200 000 of Revenue Generated From the Five Year 2420 000 000 Exclusive Purchase Order 2095 2Millennium Ships and Records the First 24200 000 of Revenue Generated From the Five Year 2420 000 000 Exclusive Purchase Order 2095 3PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 1PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 2PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 3PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 4PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 5PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 6PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 7PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 8PROCRIT 28R 29 28Epoetin Alfa 29 Data to be Presented at American Society of Hematology Annual Meeting 997 9
...curs at the 55th Annual,Clinical Meeting of the Am... COLLEGEVILLE, Pa., May 09, 2007 /PRNewswire-First...h , presented results from the,first Phase 3 studi... treatment of moderate-to-severe vasomotor symptom...enopause. These studies showed,that women who took...
...- Results of a Phase 2a,clinical trial evaluating ...eat hospital acquired gram-negative bacterial,pneu...ociety (ATS),International Conference, May 18 - 23...S. Niederman, MD, Chairman, Department of, ...or of, Medicine; Vice Chairman, Departme...
Other Medicine Technology:Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 2Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 3Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 4Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 5Wyeth Presents Phase 3 Data for Pristiq, an Investigational,Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats 6Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: